argenex SE $ARGX Shares Sold by Moore Capital Management LP

Moore Capital Management LP decreased its holdings in shares of argenex SE (NASDAQ:ARGX) by 68.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,000 shares of the company’s stock after selling 32,000 shares during the quarter. Moore Capital Management LP’s holdings in argenex were worth $11,063,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Laird Norton Wetherby Wealth Management LLC boosted its position in argenex by 2.7% during the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,253 shares of the company’s stock worth $924,000 after purchasing an additional 33 shares during the period. Lighthouse Investment Partners LLC purchased a new position in argenex in the third quarter valued at about $3,098,000. Integrated Wealth Concepts LLC lifted its stake in shares of argenex by 7.0% during the third quarter. Integrated Wealth Concepts LLC now owns 609 shares of the company’s stock worth $449,000 after purchasing an additional 40 shares in the last quarter. HighVista Strategies LLC lifted its stake in shares of argenex by 68.4% during the third quarter. HighVista Strategies LLC now owns 4,068 shares of the company’s stock worth $3,000,000 after purchasing an additional 1,653 shares in the last quarter. Finally, Hilltop Holdings Inc. boosted its position in shares of argenex by 40.3% in the third quarter. Hilltop Holdings Inc. now owns 929 shares of the company’s stock worth $685,000 after buying an additional 267 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Trading Up 0.4%

Shares of NASDAQ ARGX opened at $703.30 on Tuesday. The company has a market capitalization of $43.52 billion, a price-to-earnings ratio of 36.03, a price-to-earnings-growth ratio of 1.16 and a beta of 0.38. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The business has a 50 day simple moving average of $802.05 and a 200-day simple moving average of $817.48.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.05 by $1.97. The firm had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. argenex had a return on equity of 38.51% and a net margin of 30.42%. As a group, equities analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Royal Bank Of Canada lowered their target price on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Wells Fargo & Company reduced their price target on argenex from $1,317.00 to $1,247.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Citizens Jmp upped their price target on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research report on Monday, March 9th. Finally, Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $999.22.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.